<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689793</url>
  </required_header>
  <id_info>
    <org_study_id>Iron-0508-PMU</org_study_id>
    <nct_id>NCT00689793</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors</brief_title>
  <acronym>ferdon</acronym>
  <official_title>Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors : a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Lausanne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the subjective response of iron substitution
      (Tardyferon®) on fatigue in women blood donors with a mean serum ferritin &lt; 30ng/ml and to
      assess variation of ferritin and hemoglobin after a blood donation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Actually, there's no recommendation to check ferritin level in blood donors, even if
           several studies pointed out the high prevalence of iron deficiency after a blood
           donation. Furthermore, some clinical trials showed that non-anaemic women with
           unexplained fatigue may benefit from iron supplementation.

        -  The purpose of this study is to determine the subjective response of iron substitution
           (Tardyferon®) on fatigue in women blood donors with a mean serum ferritin &lt; 30ng/ml and
           to assess variation of ferritin and hemoglobin after a blood donation.

        -  We will measure blood count, ferritin level and C-reactive protein at the time of the
           blood donation and then after a week, a month and 3 months.

      A week after the blood donation, donors with a ferritin level &lt;30 ng/ml and hemoglobin &gt;
      120g/l (non anaemic) will be included in the study and randomised. A one-month iron treatment
      vs placebo will be introduced. To assess the subjective response on fatigue, the donors will
      fill in different questionnaires at the time of the blood donation and then after a week, a
      month and 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale.</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>The level of fatigue perceived at baseline and after 4 weeks was scored on a 10-point visual analogue scale ranging from &quot;no fatigue=0&quot; to &quot;very severe fatigue=10&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Variation Before and After Treatment vs Placebo</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>The level of hemoglobin measured 4 weeks after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin Change Before and After 4 Weeks of Treatment/Placebo</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>Level of ferritin measured 4 weeks after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aerobic Capacity Using an Indirect Measurement of VO2Max : Chester Step Test</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>Subjects were asked to step on to and off a 20cm step at a rate set by a metronome. Step rate increased gradually until subject reached her submaximal predicted heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of Iron Supplementation on Mental Disorder</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>Depression was assessed using the Prime-MD Patient Health Questionnaire (PHQ-9), self-administered by the subject.Diagnosis of depression syndrom was made scoring results of the nine item (range : 0-3). A score &gt;15 (range of total overall scale:0-27) was considered as a depression syndrome. The outcome measure is the number the donors with a depression syndrome at baseline who had a positive response (total score= or &lt;15) after placebo or treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Treatment.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adherence to treatment was calculated as the number of days with at least one opening of the electronic device divided by the total number of monitored days. The device was a MEMS (Medication Event Monitoring System,AARDEX, Europe, Switzerland)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Fatigue</condition>
  <condition>Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous sulphate</intervention_name>
    <description>Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue (&quot; Fatigue Severity Scale&quot;). We will also check depression and anxiety symptoms (&quot; Prime MD &quot;) and health survey (&quot; SF-12 &quot;). An evaluation of the menstruation (&quot; Pictorial Bleeding Assessment Chart &quot; of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Iron treatment</other_name>
    <other_name>Ferrous sulphate treatment</other_name>
    <other_name>Tardyferon</other_name>
    <other_name>Robapharm</other_name>
    <other_name>Fer</other_name>
    <other_name>Sulphate de fer</other_name>
    <other_name>Sulphate ferreux</other_name>
    <other_name>Iron deficiency</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue (&quot; Fatigue Severity Scale&quot;). We will also check depression and anxiety symptoms (&quot; Prime MD &quot;) and health survey (&quot; SF-12 &quot;). An evaluation of the menstruation (&quot; Pictorial Bleeding Assessment Chart &quot; of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Iron treatment</other_name>
    <other_name>Ferrous sulphate treatment</other_name>
    <other_name>Tardyferon</other_name>
    <other_name>Robapharm</other_name>
    <other_name>Fer</other_name>
    <other_name>Sulphate de fer</other_name>
    <other_name>Sulphate ferreux</other_name>
    <other_name>Iron deficiency</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women

          -  aged 18 - 50

          -  eligible for a blood donation

        Exclusion Criteria:

          -  men

          -  age below 18 or above 50

          -  not eligible for a blood donation (according to the blood donation eligibility
             guidelines of the Swiss Red Cross)

          -  hemochromatosis, psychiatric / thyroid / hepatic / rheumatismal / kidney or
             cardiopulmonary diseases that can cause fatigue

          -  intestinal disease or medical treatment that can perturb iron absorption and/or
             excretion

          -  donors with mental disorder or psychiatric disease that are unable to give consent

          -  acute or chronic inflammation

          -  diabetes and pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Favrat, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Amulatory Care and Community Medicine, University of Lausanne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baptiste Pedrazzini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Amulatory Care and Community Medicine, University of Lausanne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Cornuz, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Amulatory Care and Community Medicine, University of Lausanne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Pécoud, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Amulatory Care and Community Medicine, University of Lausanne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie Waldvogel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Blood Transfusion Department, University Hospitals of Lausanne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Daniel Tissot, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Blood Transfusion Department, University Hospitals of Lausanne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ambulatory Care and Community Medicine, University Hospitals of Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>Bugnon 44</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, Bischoff T, de Vevey M, Studer JP, Herzig L, Chapuis C, Tissot J, Pécoud A, Favrat B. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. 2003 May 24;326(7399):1124.</citation>
    <PMID>12763985</PMID>
  </reference>
  <reference>
    <citation>Patterson AJ, Brown WJ, Powers JR, Roberts DC. Iron deficiency, general health and fatigue: results from the Australian Longitudinal Study on Women's Health. Qual Life Res. 2000;9(5):491-7.</citation>
    <PMID>11190004</PMID>
  </reference>
  <reference>
    <citation>BEUTLER E, LARSH SE, GURNEY CW. Iron therapy in chronically fatigued, nonanemic women: a double-blind study. Ann Intern Med. 1960 Feb;52:378-94.</citation>
    <PMID>13800263</PMID>
  </reference>
  <reference>
    <citation>Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996 Oct 12;348(9033):992-6.</citation>
    <PMID>8855856</PMID>
  </reference>
  <reference>
    <citation>Patterson AJ, Brown WJ, Roberts DC. Dietary and supplement treatment of iron deficiency results in improvements in general health and fatigue in Australian women of childbearing age. J Am Coll Nutr. 2001 Aug;20(4):337-42.</citation>
    <PMID>11506061</PMID>
  </reference>
  <reference>
    <citation>Newman BH, Roth AJ. Estimating the probability of a blood donation adverse event based on 1000 interviewed whole-blood donors. Transfusion. 2005 Nov;45(11):1715-21.</citation>
    <PMID>16271095</PMID>
  </reference>
  <reference>
    <citation>Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed. Transfusion. 2006 Oct;46(10):1667-81. Review.</citation>
    <PMID>17002622</PMID>
  </reference>
  <reference>
    <citation>Maghsudlu M, Nasizadeh S, Toogeh GR, Zandieh T, Parandoush S, Rezayani M. Short-term ferrous sulfate supplementation in female blood donors. Transfusion. 2008 Jun;48(6):1192-7. doi: 10.1111/j.1537-2995.2007.01671.x. Epub 2008 Mar 17.</citation>
    <PMID>18363581</PMID>
  </reference>
  <reference>
    <citation>Magnussen K, Bork N, Asmussen L. The effect of a standardized protocol for iron supplementation to blood donors low in hemoglobin concentration. Transfusion. 2008 Apr;48(4):749-54. doi: 10.1111/j.1537-2995.2007.01601.x. Epub 2008 Jan 8.</citation>
    <PMID>18194390</PMID>
  </reference>
  <reference>
    <citation>Brownlie T 4th, Utermohlen V, Hinton PS, Giordano C, Haas JD. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr. 2002 Apr;75(4):734-42.</citation>
    <PMID>11916761</PMID>
  </reference>
  <reference>
    <citation>Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 Oct;46(10):1121-3.</citation>
    <PMID>2803071</PMID>
  </reference>
  <reference>
    <citation>Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999 Nov 10;282(18):1737-44.</citation>
    <PMID>10568646</PMID>
  </reference>
  <reference>
    <citation>Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998 Nov;51(11):1171-8.</citation>
    <PMID>9817135</PMID>
  </reference>
  <reference>
    <citation>Janssen CA. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Eur J Obstet Gynecol Reprod Biol. 1996 Dec;70(1):21-2. Review.</citation>
    <PMID>9031914</PMID>
  </reference>
  <reference>
    <citation>Buckley JP, Sim J, Eston RG, Hession R, Fox R. Reliability and validity of measures taken during the Chester step test to predict aerobic power and to prescribe aerobic exercise. Br J Sports Med. 2004 Apr;38(2):197-205.</citation>
    <PMID>15039259</PMID>
  </reference>
  <results_reference>
    <citation>Waldvogel S, Pedrazzini B, Vaucher P, Bize R, Cornuz J, Tissot JD, Favrat B. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. BMC Med. 2012 Jan 24;10:8. doi: 10.1186/1741-7015-10-8.</citation>
    <PMID>22272750</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <results_first_submitted>May 18, 2012</results_first_submitted>
  <results_first_submitted_qc>January 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 15, 2013</results_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne</investigator_affiliation>
    <investigator_full_name>Bernard Favrat</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Fatigue</keyword>
  <keyword>Blood donation</keyword>
  <keyword>Iron deficiency</keyword>
  <keyword>Ferrous sulphate</keyword>
  <keyword>Donation</keyword>
  <keyword>Donors</keyword>
  <keyword>Iron</keyword>
  <keyword>Ferritin</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Anemia</keyword>
  <keyword>Anaemia</keyword>
  <keyword>Haemoglobin</keyword>
  <keyword>Don</keyword>
  <keyword>Women blood donors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Premopausal female blood donors coming spontaneously to the donation center, were asked to participated to this study. After agreement an informed consent was signed.</recruitment_details>
      <pre_assignment_details>One week after whole blood donation, participants were randomized if they were not anemic and their ferritin level was &lt; or = 30 ng/mL.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Treatment of Iron</title>
          <description>One week after donation, donors self-administered ferrous sulfate (80mg of elemental iron daily) during one month.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>One week after donation, donors self-administered on pill of placebo (daily), during one month.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Treatment of Iron</title>
          <description>One week after donation, donors self-administered ferrous sulfate (80mg of elemental iron daily) during one month.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>One week after donation, donors self-administered on pill of placebo (daily), during one month.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.9" spread="8.4"/>
                    <measurement group_id="B2" value="30.7" spread="8.8"/>
                    <measurement group_id="B3" value="31.6" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale.</title>
        <description>The level of fatigue perceived at baseline and after 4 weeks was scored on a 10-point visual analogue scale ranging from &quot;no fatigue=0&quot; to &quot;very severe fatigue=10&quot;.</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>The sample size for randomized volunteers was calculated using a two-sample comparison of means to detect a one point difference in the visual analogical scale (first outcome).</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Treatment of Iron</title>
            <description>One week after donation, donors self-administered ferrous sulfate (80mg of elemental iron daily) during one month.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One week after donation, donors self-administered one pill of placebo (daily), during 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale.</title>
          <description>The level of fatigue perceived at baseline and after 4 weeks was scored on a 10-point visual analogue scale ranging from &quot;no fatigue=0&quot; to &quot;very severe fatigue=10&quot;.</description>
          <population>The sample size for randomized volunteers was calculated using a two-sample comparison of means to detect a one point difference in the visual analogical scale (first outcome).</population>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.4"/>
                    <measurement group_id="O2" value="3.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in fatigue VAS scores between the treatment and placebo groups at 4 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <p_value_desc>Significant level of treatment effect was set at p&lt;0.05</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Level of fatigue at four weeks:dependant variable. Group allocation and level of fatigue at baseline: independant variables.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Variation Before and After Treatment vs Placebo</title>
        <description>The level of hemoglobin measured 4 weeks after randomization</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>The number of participants was calculated according to the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Treatment of Iron</title>
            <description>One week after donation, donors self-administered ferrous sulfate (80mg of elemental iron daily), during one month.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One week after donation, donors self-administered on pill of placebo (daily), during one month.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Variation Before and After Treatment vs Placebo</title>
          <description>The level of hemoglobin measured 4 weeks after randomization</description>
          <population>The number of participants was calculated according to the primary outcome.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" spread="6.7"/>
                    <measurement group_id="O2" value="130" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
            <method_desc>Hemoglobin value at four weeks : dependant variable. Group allocation and hemoglobin value at baseline : independant variables.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ferritin Change Before and After 4 Weeks of Treatment/Placebo</title>
        <description>Level of ferritin measured 4 weeks after randomization</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Treatment of Iron</title>
            <description>One week after donation, donors self-administered ferrous sulfate (80mg of elemental iron daily) during one month.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One week after donation, donors self-administered on pill of placebo (daily), during one month.</description>
          </group>
        </group_list>
        <measure>
          <title>Ferritin Change Before and After 4 Weeks of Treatment/Placebo</title>
          <description>Level of ferritin measured 4 weeks after randomization</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" spread="9.8"/>
                    <measurement group_id="O2" value="12.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
            <method_desc>Ferritin level at 4 weeks : dependant variable. Group allocation and ferritin level at baseline: independant variables.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aerobic Capacity Using an Indirect Measurement of VO2Max : Chester Step Test</title>
        <description>Subjects were asked to step on to and off a 20cm step at a rate set by a metronome. Step rate increased gradually until subject reached her submaximal predicted heart rate.</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Treatment of Iron</title>
            <description>One week after donation, donors self-administered ferrous sulfate (80mg of elemental iron daily) during one month.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One week after donation, donors self-administered on pill of placebo (daily), during one month.</description>
          </group>
        </group_list>
        <measure>
          <title>Aerobic Capacity Using an Indirect Measurement of VO2Max : Chester Step Test</title>
          <description>Subjects were asked to step on to and off a 20cm step at a rate set by a metronome. Step rate increased gradually until subject reached her submaximal predicted heart rate.</description>
          <units>mLO2/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" spread="14.5"/>
                    <measurement group_id="O2" value="40.1" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Regression, Linear</method>
            <method_desc>Aerobic capacity at 4 weeks : dependant variables. Group allocation and aerobic capacity at baseline : independant variable.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response of Iron Supplementation on Mental Disorder</title>
        <description>Depression was assessed using the Prime-MD Patient Health Questionnaire (PHQ-9), self-administered by the subject.Diagnosis of depression syndrom was made scoring results of the nine item (range : 0-3). A score &gt;15 (range of total overall scale:0-27) was considered as a depression syndrome. The outcome measure is the number the donors with a depression syndrome at baseline who had a positive response (total score= or &lt;15) after placebo or treatment.</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Number of participant was set according the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Treatment of Iron</title>
            <description>One week after donation, donors self-administered ferrous sulfate (80mg of elemental iron daily) during one month.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One week after donation, donors self-administered on pill of placebo (daily), during one month.</description>
          </group>
        </group_list>
        <measure>
          <title>Response of Iron Supplementation on Mental Disorder</title>
          <description>Depression was assessed using the Prime-MD Patient Health Questionnaire (PHQ-9), self-administered by the subject.Diagnosis of depression syndrom was made scoring results of the nine item (range : 0-3). A score &gt;15 (range of total overall scale:0-27) was considered as a depression syndrome. The outcome measure is the number the donors with a depression syndrome at baseline who had a positive response (total score= or &lt;15) after placebo or treatment.</description>
          <population>Number of participant was set according the primary outcome.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to Treatment.</title>
        <description>Adherence to treatment was calculated as the number of days with at least one opening of the electronic device divided by the total number of monitored days. The device was a MEMS (Medication Event Monitoring System,AARDEX, Europe, Switzerland)</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Treatment of Iron</title>
            <description>One week after donation, donors self-administered ferrous sulfate (80mg of elemental iron daily) during one month.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One week after donation, donors self-administered on pill of placebo (daily), during one month.</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Treatment.</title>
          <description>Adherence to treatment was calculated as the number of days with at least one opening of the electronic device divided by the total number of monitored days. The device was a MEMS (Medication Event Monitoring System,AARDEX, Europe, Switzerland)</description>
          <units>percentage of day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" spread="16.7"/>
                    <measurement group_id="O2" value="96" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>adverse events were reported during the 4 weeks of treatment/placebo</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Treatment of Iron</title>
          <description>One week after donation, donors self-administered ferrous sulfate (80mg of elemental iron daily) during one month.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>One week after donation, donors self-administered on pill of placebo (daily), during one month.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastro-intestinal events</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="74"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>other events (not serious)</sub_title>
                <description>dizziness (n=3), headache (n=2), acne (n=2), palpitations (n=1), and renal lithiasis (n=1)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Bernard Favrat MD</name_or_title>
      <organization>Departement of ambulatory care and community medicine, University of Lausanne, Switzerland</organization>
      <phone>+41795566183314</phone>
      <email>Bernard.favrat@chuv.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

